Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early octreotide plus selective COX-2 inhibitor for predicted severe acute pancreatitis
ChiCTR-TRC-14005059Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2014
- Modality
- Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of octreotide, parecoxib and celecoxib in acute pancreatitis (AP) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Incidence of severe acute pancreatitis. Started Aug 2014; status: recruiting.
02
Drugs
octreotideparecoxibcelecoxib
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on ChiCTR-TRC-14005059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14005059.